Investigating how Endothelin 1 affects iron handling in sickle cell disease
Endothelin 1 in iron handling in sickle cell disease
This study is looking at how a substance called Endothelin 1 affects iron buildup in the kidneys of people with sickle cell disease, and it hopes to find new ways to lower that iron and help keep their kidneys healthy.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Univ of North Carolina Chapel Hill NIH-funded |
| Lab location | 1 site (Chapel Hill, United States) |
| Project ID | NIH-11047817 on NIH RePORTER |
What this research studies
This research focuses on understanding the role of Endothelin 1 (ET-1) in the accumulation of iron in the kidneys of patients with sickle cell disease (SCD). It aims to explore the mechanisms behind kidney iron overload, which is a significant complication for many SCD patients. By studying both human patients and animal models, the research will assess how targeting ET-1 with specific antagonists can reduce kidney iron levels and improve kidney function. The ultimate goal is to develop new treatment strategies that can protect the kidneys from damage caused by excess iron.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals with sickle cell disease, particularly those experiencing kidney complications.
Not a fit: Patients without sickle cell disease or those who do not have kidney-related issues may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that prevent kidney damage in sickle cell disease patients.
How similar studies have performed: Previous studies have shown promising results in targeting similar pathways for iron overload in other conditions, suggesting potential for success in this novel approach.
Where this research is happening
Chapel Hill, United States
- Univ of North Carolina Chapel Hill — Chapel Hill, United States (Active)
Researchers
- Principal investigator: Kasztan, Malgorzata — Univ of North Carolina Chapel Hill
- Study coordinator: Kasztan, Malgorzata
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.